JP Morgan Asset Management, a capital market company, led a $100m Series A round in Enlaza Therapeutics, a covalent biologic platform company, with participation from Frazier Life Sciences, Avalon Ventures, Lightspeed Venture Partners, Samsara BioCapital, Amgen Ventures, Regeneron Ventures, Bregua Corporation, Pappas Capital, and Alexandria Venture Investments. “We are thrilled to close this financing with a group of new and existing investors that share our vision of creating a novel, differentiated class of protein therapeutics in oncology and other therapeutic areas. This support will enable continued expansion of our covalent protein drug platform, establishment of a diversified pipeline that demonstrates the broad potential of this approach, and advancement of our lead assets toward clinical development,” Sergio Duron, Enlaza Therapeutics CEO.